title: Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients.
abstract: Ibalizumab is a humanized monoclonal antibody that binds human CD4, the primary receptor for human immunodeficiency virus type 1 (HIV-1). With its unique specificity for domain 2 of CD4, this antibody potently and broadly blocks HIV-1 infection in vitro by inhibiting a postbinding step required for viral entry but without interfering with major histocompatibility complex class II (MHC-II)-mediated immune function. In clinical trials, ibalizumab has demonstrated anti-HIV-1 activity in patients without causing immunosuppression. Thus, a characterization of the ibalizumab epitope was conducted in an attempt to gain insight into the underlying mechanism of its antiviral activity as well as its safety profile. By studying mouse/human chimeric CD4 molecules and site-directed point mutants of CD4, amino acids L96, P121, P122, and Q163 in domain 2 were found to be important for ibalizumab binding, with E77 and S79 in domain 1 also contributing. All these residues appear to cluster on the interface between domains 1 and 2 of human CD4 on a surface opposite the site where gp120 and the MHC-II molecule bind on domain 1. Separately, the epitope of M-T441, a weakly neutralizing mouse monoclonal antibody that competes with ibalizumab, was localized entirely within domain 2 on residues 123 to 125 and 138 to 140. The results reported herein not only provide an appreciation for why ibalizumab has not had significant adverse immunological consequences in infected patients to date but also raise possible steric hindrance mechanisms by which this antibody blocks HIV-1 entry into a CD4-positive cell.
authors.affiliation: Aaron Diamond AIDS Research Center, 455 First Avenue, New York, NY, USA.
authors.forename: Ruijiang
authors.initials: R
authors.lastname: Song
authors.forename: David
authors.initials: D
authors.lastname: Franco
authors.forename: Chia-Ying
authors.initials: CY
authors.lastname: Kao
authors.forename: Faye
authors.initials: F
authors.lastname: Yu
authors.forename: Yaoxing
authors.initials: Y
authors.lastname: Huang
authors.forename: David D
authors.initials: DD
authors.lastname: Ho
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D019380:Anti-HIV Agents / Q000276:immunology / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D015704:CD4 Antigens / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D018604:Epitope Mapping; D000939:Epitopes / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D017354:Point Mutation; D011487:Protein Conformation; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D016415:Sequence Alignment; D053586:Virus Internalization
chemical_list: D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D000939:Epitopes; D011993:Recombinant Fusion Proteins; C481504:ibalizumab
references.citation: J Virol. 1999 May;73(5):4009-18
references.pmid: 10196297
references.citation: Proc Natl Acad Sci U S A. 1990 Aug;87(16):6423-7
references.pmid: 2385600
references.citation: Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7
references.pmid: 6096719
references.citation: AIDS Res Hum Retroviruses. 1995 Apr;11(4):517-25
references.pmid: 7632466
references.citation: Nature. 1997 May 29;387(6632):527-30
references.pmid: 9168119
references.citation: Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2189-93
references.pmid: 2006155
references.citation: Antimicrob Agents Chemother. 2006 Jun;50(6):2231-3
references.pmid: 16723592
references.citation: Nature. 1998 Jun 18;393(6686):648-59
references.pmid: 9641677
references.citation: Nature. 1996 Nov 14;384(6605):179-83
references.pmid: 8906795
references.citation: Nature. 1997 May 22;387(6631):426-30
references.pmid: 9163431
references.citation: Nature. 2003 Mar 20;422(6929):307-12
references.pmid: 12646921
references.citation: Curr Top Microbiol Immunol. 2008;317:39-66
references.pmid: 17990789
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10799-804
references.pmid: 11535811
references.citation: J Virol. 1992 Aug;66(8):4784-93
references.pmid: 1378510
references.citation: Antimicrob Agents Chemother. 2009 Feb;53(2):450-7
references.pmid: 19015347
references.citation: Nature. 2008 Oct 2;455(7213):613-9
references.pmid: 18833271
references.citation: Nat Med. 2000 Feb;6(2):200-6
references.pmid: 10655110
references.citation: Cell. 1997 Apr 18;89(2):263-73
references.pmid: 9108481
references.citation: Nature. 1990 Nov 29;348(6300):411-8
references.pmid: 1701030
references.citation: J Virol. 1993 Jul;67(7):3978-88
references.pmid: 7685405
references.citation: AIDS Res Hum Retroviruses. 1993 Mar;9(3):199-207
references.pmid: 8471310
references.citation: Top HIV Med. 2004 Oct-Nov;12(4):100-3
references.pmid: 15516706
references.citation: J Infect Dis. 2004 Jan 15;189(2):286-91
references.pmid: 14722894
references.citation: Nature. 2008 Sep 4;455(7209):109-13
references.pmid: 18668044
references.citation: J Biol Chem. 2008 Feb 1;283(5):2761-72
references.pmid: 18045872
references.citation: Cell. 1985 Aug;42(1):93-104
references.pmid: 2990730
references.citation: Curr Opin Investig Drugs. 2007 Aug;8(8):653-61
references.pmid: 17668367
references.citation: J Infect Dis. 2008 Nov 1;198(9):1345-52
references.pmid: 18771406
references.citation: J Immunol. 1992 Sep 1;149(5):1779-87
references.pmid: 1380539
references.citation: J Virol. 1995 Sep;69(9):5723-33
references.pmid: 7543586
references.citation: Toxicology. 2002 Apr 2;172(3):191-203
references.pmid: 11893418
references.citation: Nature. 1990 Nov 29;348(6300):419-26
references.pmid: 2247146
references.citation: Cell. 1986 Nov 7;47(3):333-48
references.pmid: 3094962